Collaboration Demonstrates the Unique Capabilities of its QPOR Platform in Determining Quality H&E Staining Protocols Needed for Accurate Diagnosis
Newton, Massachusetts, Sept. 7, 2023 – 4D Path, a pioneer in image analysis and developer of the 4D Q-Plasia Oncoreader (QPOR)TM, today announced the company and its collaborators, Evident Scientific and Sakura Finetek USA, will present a new study at the 2023 National Society for Histotechnology (NSH) Convention from September 8-12 in Baltimore, Maryland.
4D Path is advancing tumor profiling and therapeutic decision support by developing an Augmented Intelligence platform that is designed to help pathologists and oncologists make accurate, quantitatively-driven diagnostic decisions. The company applies statistical physics and tumor biology to routine H&E tissue image data resulting in the identification of aberrant patterns within regulatory pathways found in cancer cell biology.
The collaboration builds on the strengths of each organization to address needs within histopathology, including the challenges of identifying staining protocols customized for individual laboratory conditions, starting with the selection of tissue controls and ending with a quantitative measurement for adequacy. By utilizing digital images and an automated image analysis system, the team identified H&E staining protocols that are robust in providing identification of areas of cancer. The development of an objective analysis that is both automated and reproducible, is needed to achieve a viable and scalable digital pathology workflow.
Kam Patel, President and COO, Sakura Finetek USA, said, “Laboratory automation in histopathology benefits from a standardized measurement of H&E stain adequacy. Being part of the development of a breakthrough tool based on image analysis supports our vision of advancing cancer diagnostics by providing integrated solutions for anatomic pathology and patients through best-in-class innovation, quality, and customer care.”
Tathagata Dasgupta, President and CTO, 4D Path, added, “Fully automated digital pathology workflow requires quantitative quality assessment. 4D Path’s science-driven platform, aiming to support pathology and oncology decision making, can potentially serve the purpose of being a stable and consistent predictive image analysis system. Validating our platform’s ability to qualify H&E staining adequacy with varying staining protocols is an important step forward. We are excited to partner with Sakura Finetek USA, a global leader in histopathology products, and Evident Scientific, a global leader in microscopy and imaging solutions, to align on the mutually beneficial path towards building a robust digital pathology quality control system and, ultimately, achieving the common goal of making cancer care better.”
The new study will be presented during the NSH Vendor Expo & Scientific Posters session (details below). The organizations will continue to build on this work and look to identify future applications for this important diagnostic advancement.
Title: Automated Robust Image Analysis Qualifying H&E Staining Adequacy with Varying Hematoxylin and Eosin Incubation Times
Authors: Satabhisa Mukhopadhyay1, PhD, 4D Path, Newton, MA; Tathagata Dasgupta1, PhD, 4D Path, Newton, M; Christopher Higgins2, Evident Scientific, Waltham, MA; Alec DeGrand2, MBA BS, Evident Scientific, Waltham, MA; Lisa M. Williams1, PhD, 4D Path, Newton, MA; Nicolas Orsi, MBChB PhD MRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Judy Lapetino3, Sakura Finetek USA, Torrance, CA; Erico von Bueren3, MD PhD MOR, Sakura Finetek USA, Torrance, CA
Date/Time: Monday, September 11 at 12:00 PM EDT
* Disclosures: All authors are employed with their respective companies.
* Disclaimer: This study does not promote any in-vitro diagnostic use.
About 4D Path
Just because you can’t see something, doesn’t mean it’s not there. 4D Path’s mission is to transform precision diagnostics by using statistical physics and cell cycle dynamics to unveil previously hidden information in cellular snapshots of tissue. The company’s cloud-based 4D Q-Plasia OncoReaderTM (QPOR) is a U.S. patented pan-cancer platform, which has also been awarded FDA Breakthrough Device Designation for its Breast Cancer-specific QPOR. This digital image-to-report solution provides a tool which aims to improve diagnostic accuracy of existing biomarkers, identify new biological signatures to guide therapeutic management, accelerate diagnostic turnaround times, and reduce costs in a single step. 4D Path collaborates with a broad array of clinical and life science partners to advance the field of precision medicine through groundbreaking cancer diagnostic technology.
Visit www.4dpath.com or contact Lisa Williams, lwilliams@4dpath.com, to learn more.
About Sakura Finetek USA, Inc.
With the U.S. office based in Torrance, California, Sakura Finetek is the global leader in continuous innovation for pathology by providing integrated solutions for anatomic pathology and patients through best-in-class innovation, quality, and customer care. With a strategic focus on end-to-end automation, Sakura Finetek continues to lead the industry in the development and commercialization of automated histology instrumentation and consumables for anatomic pathology. Sakura Finetek solutions dramatically increase efficiency, standardize results, and enable pathology laboratories to more simply manage their daily workload while significantly impacting patient care.
Visit www.sakuraus.com to learn more.
About EVIDENT
At Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people’s lives healthier, safer, and more fulfilling, we support our customers with solutions that solve their challenges and advance their work, whether it is researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products. Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF, and other clinical applications as well as for research and education.
For more information, visit www.EvidentScientific.com.
4D Path PR Contact
Jill Anderson / Laura Nelson
SVM PR & Marketing Communications
Jill.anderson@svmpr.com / Laura.nelson@svmpr.com
(401) 490-9700
Sakura Finetek PR Contact
Erico von Bueren MD PhD MOR
Senior Director of Marketing and Strategy
Sakura Finetek USA, Inc.
1750 W. 214th St.
Torrance, CA 90501
evonbueren@sakuraus.com
